CytomX Therapeutics, Inc. (CTMX) News
Filter CTMX News Items
CTMX News Results
|Loading, please wait...|
CTMX News Highlights
- For CTMX, its 30 day story count is now at 7.
- Over the past 24 days, the trend for CTMX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- CX, DRUG and LUNG are the most mentioned tickers in articles about CTMX.
Latest CTMX News From Around the Web
Below are the latest news stories about CytomX Therapeutics Inc that investors may wish to consider to help them evaluate CTMX as an investment opportunity.
The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that on January 18, 2022, the Company granted four new employees options to purchase a total of 127,000 shares of the Company’s common stock at an exercise price per share equal to $3.83, which was the closing trading price on January 18, 2022, the date of the grant. The stock options were granted pursuant to the C
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
- CX-904 is CytomX’s first T-cell-engaging bispecific antibody and the sixth Probody® therapeutic candidate to enter the clinic -SOUTH SAN FRANCISCO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for CX-904, an EGFRxCD3 T-cell-engaging bispecific antibody being co-
In this article, we discuss the 10 small-cap stocks to buy according to billionaire Steve Cohen. You can skip our detailed analysis of Steve Cohen’s hedge fund, and go directly to read 5 Small-Cap Stocks to Buy According to Billionaire Steve Cohen. Billionaire investor Steve Cohen is the brain behind Point72 Asset Management, a hedge fund […]
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th at 3:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.
An investment in a biotech company is not without risk, and last week, CytomX Therapeutics (CTMX) investors got a painful reminder of the consequences should clinical testing not go as hoped for. Shares dropped by 40% in a single session after the data from the Phase 2 trial of experimental cancer therapy CX-2029 failed to impress. The study was assessing the drug as a treatment for patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell carcinoma (HNSCC). For the former group, the data showed an objective response rate (ORR) of 18.8% and a disease-control rate (DCR) of 87.
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Esperion (ESPR – Research Report) and CytomX Therapeutics (CTMX – Research Report). Esperion (ESPR) J.P. Morgan analyst Jessica Fye maintained a Sell rating on Esperion yesterday and set a price target of $6.00. The company's shares closed last Wednesday at $5.15, close to its 52-week low of $4.85. According to TipRanks.
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Chimerix (CMRX) and CytomX Therapeutics (CTMX)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (LGND – Research Report), Chimerix (CMRX – Research Report) and CytomX Therapeutics (CTMX – Research Report) with bullish sentiments. Ligand Pharma (LGND) H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma today and set a price target of $310.00. The company's shares closed last Tuesday at $151.02. According to TipRanks.
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CytomX Therapeutics (CTMX – Research Report) and Passage Bio (PASG – Research Report) with bullish sentiments. CytomX Therapeutics (CTMX) In a report released yesterday, Kaveri Pohlman from BTIG maintained a Buy rating on CytomX Therapeutics, with a price target of $16.00. The company's shares closed last Monday at $6.45. According to TipRanks.
Good morning, trader!